<DOC>
	<DOCNO>NCT02947867</DOCNO>
	<brief_summary>A prospective , randomised , placebo-controlled , double-masked , three-armed multi-centre phase II/III trial Study Topical Treatment Ischaemic Central Retinal Vein Occlusion Prevent Neovascular Glaucoma - STRONG Study</brief_summary>
	<brief_title>Trial Aganirsen iCRVO Patients Risk Developing NVG</brief_title>
	<detailed_description>The STRONG Study phase II/III prospective , randomise , placebo-controlled , double-masked , three-armed multi-centre study aganirsen antisense oligonucleotide , topical treatment iCRVO intend prevent Neovascular Glaucoma ( NVG ) . The study evaluate efficacy two different dos aganirsen formulate eye emulsion avoid new vessel formation block Insulin Receptor Substrate ( IRS ) -1 . Eligible patient treat aganirsen placebo period 24 week . They also invite participate sub-studies work analysis gonioscopic image , detection biomarkers neovascular glaucoma risk factor ischaemic central retinal vein occlusion .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Glaucoma , Neovascular</mesh_term>
	<criteria>Subjects meet follow criterion consider enrolment trial : Male female ≥ 18 year IOP study eye ≤ 21mmHg Primary ischaemic CRVO conversion ischaemic CRVO study eye longer 4 week Bestcorrected visual acuity ( BCVA ) ETDRS letter score &lt; 35 ( &lt; 20/200 Snellen equivalent ) study eye ≥ 10disc area retinal capillary obliteration fluorescein fundus angiography study eye ( central fundus : macular area define optic disc arcade , approximate 6000 micron circle around fovea ) and/or large , confluent retinal haemorrhage study eye Must accompany 4 6 follow criterion : A relative afferent pupillary defect ( normal fellow eye ) ≥ 10 cottonwoolspots study eye Venous tortuosity study eye Peripheral visual field defect correspond ischaemia ( Goldmann perimeter semiautomatic kinetic method ) study eye Engorged vessel iris and/or chamber angle study eye Detectable anterior chamber flare study eye Subjects present 1 follow criterion enrol trial : Ocular condition poorer prognosis fellow eye study eye Primary secondary glaucoma study eye Prior concomitant ocular treatment antiVEGF study eye ( ranibizumab/bevacizumab allow within last 45 day , aflibercept within last 90 day ) screen visit Use antiVEGF treatment fellow eye trial Previous use intraocular corticosteroid time use periocular corticosteroid study eye within 90 day prior screen visit History idiopathic autoimmune uveitis either eye Presence NVD , NVE anterior segment neovascularisation ( NVA NVI ) study eye Previous PRP study eye Intraocular surgery ( intravitreal antiVEGF treatment ) laser treatment study eye within past 90 day screen visit Patients history breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>